# Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL)

> **NCT06050694** · PHASE2 · RECRUITING · sponsor: **University Health Network, Toronto** · enrollment: 40 (estimated)

## Conditions studied

- Diffuse Large B Cell Lymphoma (DLBCL)

## Interventions

- **DRUG:** glofitamab

## Key facts

- **NCT ID:** NCT06050694
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-24
- **Primary completion:** 2027-11
- **Final completion:** 2027-11
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06050694

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06050694, "Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06050694. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*